Kiniksa (KNSA) CAO nets shares after 3,932 RSUs vest and 1,666 withheld for taxes

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna exercised restricted share units and had shares withheld for taxes. On this date, 3,932 Restricted Share Units converted into 3,932 Class A Ordinary Shares. Of these, 1,666 shares were disposed of to cover tax obligations at a price of $48.94 per share, a non-market tax-withholding transaction. After these compensation-related events, Megna directly held 34,043 Class A Ordinary Shares. The RSUs vest over four years, with 25% vesting on each yearly anniversary of the April 7, 2022 grant date.

Insider Trade Summary

3,932 shares exercised/converted

Mixed 3 txns

Insider Megna Michael R

Role CHIEF ACCOUNTING OFFICER

Type	Security	Shares	Price	Value
Exercise	Restricted Share Unit	3,932	$0.00	--
Exercise	Class A Ordinary Share	3,932	$1.00	$4K
Tax Withholding	Class A Ordinary Share	1,666	$48.94	$82K

Holdings After Transaction: Restricted Share Unit — 0 shares (Direct); Class A Ordinary Share — 35,709 shares (Direct)

Footnotes (1)

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

Key Figures

RSUs exercised: 3,932 units Shares withheld for taxes: 1,666 shares at $48.94 Shares held after transaction: 34,043 shares +1 more

4 metrics

RSUs exercised 3,932 units Restricted Share Units converting into Class A Ordinary Shares on April 7, 2026

Shares withheld for taxes 1,666 shares at $48.94 Tax-withholding disposition of Class A Ordinary Shares

Shares held after transaction 34,043 shares Direct Class A Ordinary Share holdings following the reported transactions

RSU vesting pattern 25% per year over 4 years RSUs granted April 7, 2022 vest annually in four equal installments

Key Terms

Restricted Share Unit, tax-withholding disposition, Class A Ordinary Share

3 terms

Restricted Share Unit financial

"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

tax-withholding disposition financial

"Payment of exercise price or tax liability by delivering securities"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Class A Ordinary Share financial

"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer"

A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Megna Michael R

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	04/07/2026		M		3,932	A	$1(1)	35,709	D
Class A Ordinary Share	04/07/2026		F		1,666	D	$48.94	34,043	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Unit	(1)	04/07/2026		M			3,932	(2)	(2)	Class A Ordinary Share	3,932	$0	0	D

Explanation of Responses:

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

	/s/ Douglas Barry, Attorney-in-Fact	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kiniksa (KNSA) report for Michael R. Megna?

Kiniksa reported that chief accounting officer Michael R. Megna exercised 3,932 Restricted Share Units into 3,932 Class A Ordinary Shares. As part of this compensation event, 1,666 shares were withheld to cover tax obligations, leaving him with 34,043 Class A Ordinary Shares held directly.

How many KNSA shares does Michael R. Megna hold after this Form 4 filing?

After the reported transactions, Michael R. Megna directly holds 34,043 Class A Ordinary Shares of Kiniksa Pharmaceuticals. This figure reflects the 3,932 shares received from RSU conversion, net of 1,666 shares disposed of to satisfy tax obligations associated with the vesting event.

Were the KNSA insider transactions open-market buys or sells?

The reported KNSA insider activity was not open-market trading. It reflects a derivative exercise where 3,932 Restricted Share Units converted into shares, and 1,666 shares were disposed of as a tax-withholding transaction, rather than discretionary market purchases or sales of the company’s stock.

What is the vesting schedule of Michael R. Megna’s KNSA Restricted Share Units?

Each Restricted Share Unit represents a contingent right to receive one Class A Ordinary Share. The RSUs vest over four years, with 25% of the units vesting on each yearly anniversary of the April 7, 2022 grant date, creating annual vesting tranches through the fourth anniversary.

At what prices were the KNSA insider transactions recorded in this filing?

The RSU conversion itself is shown at $0.00 per unit, with the resulting Class A Ordinary Shares recorded at $1.00 per share. The 1,666 shares withheld for tax obligations are reported at a price of $48.94 per share, reflecting the value used for the tax-withholding disposition.